Next-IO™ Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program

About This Program

This program aims to develop anti-BCMA × CD3 therapeutic bispecific T-cell engagers (BiTE) for immuno-oncology.

From previous studies in the field, T cell-redirecting bispecific antibodies have demonstrated impressive achievements in some patient cases, including chimeric antigen receptor T cells, immune checkpoint inhibitors and T cell-redirecting bispecific antibodies (TRBAs). In particular, because it can recognize two different epitopes on T cells and cancer cells, Bispecific Antibody is attracting increasing attention as an innovative strategy in cancer immunotherapy. Here we propose an innovative B-Cell Maturation Antigen (BCMA) bispecific T-cell engager (BiTE) for the next multiple myeloma (MM) treatment.

BCMA

BCMA is a plasma cell-specific antigen that plays an important role in regulating B cell maturation and differentiation into plasma cells. It works by participating in the proliferation-inducing ligand (APRIL). BCMA is required for long-term optimal survival of plasma cells in the bone marrow.

Highlighted Functions:

BCMA is highly expressed in MM cell lines, malignant plasma cells and increased expression levels are also found during disease progression.
BCMA is expressed on plasmacytoid dendritic cells, promoting MM cell growth, survival and drug resistance.
Overexpression of BCMA or stimulation of APRIL in MM cells by BCMA can directly upregulate key immune checkpoint molecules, which may contribute to immunosuppressive bone marrow microenvironment.

Fig.1 BCMA-based immunotherapies with multiple mechanisms of action against MM.

BCMA × CD3 in Cancer Studies

Here are some published data about BCMA × CD3 working as a potential target for cancer immunotherapy.

BCMA × CD3 Bispecific Antibody (BI 836909) eradicates established xenograft tumors and significantly prolongs survival rate.

Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program

BCMA × CD3 Bispecific Antibody shows robust anti-tumor efficacy in MM.

Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program

Ongoing Clinical Trials

Currently, several anti-BCMA × CD3 therapeutic Bispecific Antibody (called PF-06863135, REGN5458 and AMG 420, respectively) are evaluated in clinical phase 1/2 trials. Cumulative clinical data demonstrate its critical role in cancer progression and metastasis, however, safety, efficacy, and combination strategies require further confirmation.
Despite this, BCMA × CD3 Bispecific Antibody is still a compelling combination antibody target used in cancer immunotherapy. In an effort to optimally leverage BCMA-mediated immune response, our next generation of BCMA × CD3 Bispecific Antibody targeting treatment attempts to explore the combination therapy by involving other immunomodulatory agents.

Program Planning and Management

Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-BCMA × CD3 therapeutic Bispecific Antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together.

If you are interested, please feel free to contact us so that we can discuss the program and other opportunities for cooperation in detail. Look forward to cooperating with you shortly.

Reference

Hipp S., et al. A novel BCMA /CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo[J]. Leukemia, 2017.

For Research Use Only | Not For Clinical Use